18 May 2013
Keywords: merck, co/lundbeck, terminate, gaboxadol, drug, major, co
Article | 09 April 2007
US drug major Merck & Co and Denmark's H Lundbeck terminated their gaboxadol development accord after it demonstrated disappointing results
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 April 2007
17 May 2013
© 2013 thepharmaletter.com